axlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusse

  • SATT AxLR
    • SATT AxLR
    • Governance
    • Services for companies
    • Annual reports
  • Assisting you
    • Researchers
      • Call-for-projects
    • Companies
    • Startups
    • Practical guide
  • Technology offerings
    • Invest
      • In our technologies
      • In our startups
    • Technologies
    • Startups
    • AxLR TV
  • Working with AxLR
    • Purchasing & public procurement
    • Join us
    • Our startups are hiring
  • Media
    • News
    • Agenda
    • Press kit
    • Communication kit
  • Contact
English
  • French
✕
  • Home
  • LRAs
TESOVIR
16 June 2020
PSYMAGES
3 December 2019

LRAs

LRAs

DEVELOPMENT OF SPECIFIC LRAs MOLECULES TO PURGE THE LATENT PROVIRAL POOL OF HIV IN PATIENTS

Available technology

Desired partnership(s)

  • Licensing
  • Start-up

IP

  • Patent

Establishment(s)

  • Université de Montpellier
  • CNRS

Laboratory(ies)

  • Infectious Disease Research Institute of Montpellier (IDRIM)

Keywords

  • HIV
  • Shock & Kill Strategy
  • LRAs

Context

Although combined antiretroviral therapy (cART) successfully decreases plasma viremia to undetectable levels, the complete eradication of human immunodeficiency virus type 1 (HIV-1) remains impractical because of the existence of a viral reservoir. The Shock & Kill strategy is based on the use of LRAs (latency reversing agents) to re-activate reservoir quiescent cells in order to kill them. Various cytokines, protein kinase C activators/agonists, and histone deacetylase inhibitors (HDACi) have been used as LRAs, but their unacceptable side effects and/or low efficiencies limit their clinical use.

Benefits

In this project, using molecular modeling, the team has screened and selected new molecules acting as LRAs that do not target a cellular protein but a viral protein. The series was evaluated in vitro, in cellulo and ex vivo using primary quiescent cells purified from HIV-1 patients on ART.

Applications

HIV-1 infection

AVAILABLE TECHNOLOGY | HIV – Shock & Kill Strategy – LRAs

Share
0

Related posts

8 September 2021

StabCFTR


En savoir +
6 July 2021

HTLV-1


En savoir +
23 June 2021

GEOSOTECH


En savoir +
© 2023, AxLR - SATT Occitanie Méditerranée. All rights reserved. | Legal terms & Privacy policy
English
  • English
  • French